AB Ab Inc (NYSE: ABBV) qhia Q3 kho EPS ntawm $3.66, nce 29.3% Y / Y thiab ntaus qhov kev pom zoo ntawm $ 3.59.
Tag nrho kev muag khoom tau nce 3.3% Y / Y (5.4% ntawm kev ua haujlwm) mus rau $ 14.81 billion, ploj lawm qhov kev pom zoo ntawm $ 14.96 billion.
Cov ntaub ntawv tiv thaiv kab mob tau tsim $ 7.65 nphom hauv kev muag khoom, +14.6% (+16.4% ntawm kev ua haujlwm). Humira muag tau nce 2.5% rau $ 5.56 billion. Skyrizi muag tau mus txog $ 1.39 billion (+ 75.4% Y / Y), thiab Rinvoq dhia 53.5% rau $ 695 lab.
Hematologic oncology portfolio muag yog $ 1.65 billion, nqis 11.7% (-9.9% ntawm kev ua haujlwm). Imbruvica muag poob 17.4% rau $ 1.34 billion. Venclexta cov nyiaj tau los tau nce 4.5% rau $ 515 lab.
Kev muag khoom los ntawm neuroscience portfolio mus txog $ 1.67 billion, +6.7%. Kev muag khoom zoo nkauj tau nce 4% (+ 8.1% ntawm kev ua haujlwm) rau $ 1.30 nphom, nrog $ 637 lab hauv Botox muag rau kev siv tshuaj pleev ib ce.
Nyiaj faib: AbbVie tau nce cov nyiaj faib peb lub hlis twg los ntawm 5% los ntawm $ 1.41 ib feem rau $ 1.48 ib feem.
Kev taw qhia: AbbVie lees paub FY22 kho EPS kev taw qhia thiab nqaim qhov ntau ntawm $ 13.76 - $ 13.96 txog $ 13.84 - $ 13.88, piv rau qhov kev pom zoo ntawm $ 13.86.
Nqe Nqis: ABBV shares tau nce 0.71% ntawm $ 150.89 thaum lub sijhawm kev sib ntsib ua ntej ntawm daim tshev kawg rau hnub Friday.
Saib ntxiv ntawm Benzinga
Tsis txhob nco lub sijhawm ceeb toom ntawm koj cov khoom lag luam - koom Lub Npe Lub Npe Pro dawb! Sim cov cuab yeej uas yuav pab koj nqis peev smarter, sai dua, thiab zoo dua.
© 2022 Benzinga.com. Benzinga tsis muab lus qhia txog peev. Qoob loo.
Tau qhov twg los: https://finance.yahoo.com/news/abbvie-reports-mixed-earnings-tightens-123746042.html